What Is a Microdose of Tirzepatide? (The Actual Numbers)

If you're asking "what is a microdose of tirzepatide" and you want a number, not a lecture, this page is built for you. The honest answer in one line: there is no official microdose of tirzepatide — no agency, no manufacturer, and no clinical trial has ever defined one. But the term is used in a fairly consistent way online, so we can describe the range people actually mean, show exactly where it sits relative to the real approved doses, and be straight about what that number does and doesn't buy you.

The short answer: a fraction of 2.5 mg

In practice, when people say "microdose of tirzepatide" they mean a weekly dose below the 2.5 mg starting dose — usually a small fraction of it. The amounts that circulate in microdosing communities and on telehealth menus typically land somewhere in the range of roughly 0.5 mg to 2 mg once weekly, with some going lower still (a few hundred micrograms). There's no agreed cutoff, so two people "microdosing tirzepatide" may be taking very different amounts. The word microdose sounds like a defined unit; for tirzepatide, it isn't.

To see why that range is the one people land on, you have to see the real dose ladder it sits beneath.

What the approved doses actually are

Tirzepatide is the active drug in Mounjaro (type 2 diabetes) and Zepbound (weight management). Its FDA-approved label starts everyone at 2.5 mg once weekly and titrates upward in fixed steps — 2.5, 5, 7.5, 10, 12.5, up to a maximum of 15 mg once weekly — and the label is explicit that the 2.5 mg starting dose is a tolerance-building step, not a maintenance dose meant to produce the full effect¹. That ladder mirrors the doses tested in the pivotal trials.

So the reference point matters: even the lowest official rung (2.5 mg) is described by the label as a warm-up, not a therapeutic target. A "microdose" sits below that warm-up. That's the single most useful thing to understand about the number.

So what counts as a microdose, concretely?

Putting it together, a working definition of a tirzepatide microdose is: a deliberately chosen weekly dose below 2.5 mg — most commonly in the ~0.5–2 mg range, sometimes lower — held there on purpose rather than as a step toward a higher target. Three features define it:

• •Below the starting rung. It's under the 2.5 mg the label uses just to build tolerance¹.
• •Self-selected, not validated. The exact amount comes from the user, a compounding pharmacy, or a telehealth service — not from a dose-finding trial. No trial has tested any of these microdoses.
• •Usually compounded. Approved pens aren't sold in microdose strengths, so a microdose almost always means a compounded vial drawn up by hand. We walk through that math in how to reconstitute and measure a compounded GLP-1 microdose.

For the side-by-side numbers across both drugs, see the microdosing tirzepatide dose chart and the GLP-1 microdosing chart.

How tirzepatide works — and why dose size matters

Tirzepatide is a dual agonist: it activates both the GIP and the GLP-1 receptors. The GLP-1 arm drives the familiar effects — glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and a central reduction in appetite². None of that biology is in dispute. The catch is that these effects are exposure-dependent: you need enough drug present to occupy enough receptors to actually move appetite and metabolism. "The receptor is activated" is not the same as "activated enough to do what the trials showed." A microdose, by its own definition, sits at the bottom of that exposure range.

What that number probably buys you

This is where being honest about the figure matters most. Every proven tirzepatide result came from the full, titrated doses. In SURMOUNT-1, tirzepatide produced roughly 15–21% mean weight loss across its 5, 10, and 15 mg tiers — and the higher tiers produced more loss, not the same³. In the head-to-head SURPASS-2 trial, tirzepatide at 5, 10, and 15 mg beat semaglutide on weight and blood sugar, again with a clear dose gradient⁴.

The pattern is the point: within the trials, more drug meant more effect. And the cleanest dose-finding data, from a phase 2 dose-ranging trial of the related drug semaglutide, show weight loss scaling smoothly with dose — about −6.0% at the lowest dose tested up to −13.8% at the highest⁵. A microdose lives below the bottom of that curve. So the defensible expectation for a sub-2.5 mg tirzepatide dose is some effect, smaller than the headline numbers — not a discounted version of them. We lay out the full curve in GLP-1 dose-response: why lower doses do less.

"Smaller dose" is not "officially safer"

It's tempting to read "microdose" as "automatically gentler and safer." A lower dose may soften some dose-related side effects, but it doesn't make the drug class risk-free — GLP-1 agonists used for weight loss have been linked in a large real-world analysis to elevated risk of pancreatitis, bowel obstruction, and gastroparesis⁶. And because a microdose is almost always compounded and measured by hand, it carries its own hazards: a pharmacovigilance analysis of compounded GLP-1 agonists found markedly elevated reporting for preparation errors, contamination, and dosing mistakes⁷, and the only clinical literature specifically on microdosing is cautionary, warning about dosing errors and unregulated sourcing⁸. The number being small doesn't make the practice low-risk. See is compounded / microdosed GLP-1 safe?.

The bottom line

A microdose of tirzepatide isn't an official dose — it's a self-selected weekly amount below the 2.5 mg starting rung, most often in the ~0.5–2 mg range, held there on purpose. It's off-label, almost always compounded, and untested in any trial. The proven benefits all came from full titrated doses, lower doses do less, and "smaller" isn't the same as "safer." If you're weighing it, treat the number as an unproven extrapolation and decide with a qualified clinician.

For the bigger picture, start with the pillar microdosing GLP-1: what the evidence actually shows, the plain explainer what is microdosing tirzepatide?, and the parallel question the same question asked of semaglutide. To compare providers on price and oversight, see our GLP-1 microdose rankings hub.